Skip to main
RNAC
RNAC logo

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics is showing a positive outlook due to updated Phase II results that indicate durable clinical benefits lasting at least one year. The company is focusing on its innovative ImmTOR immune tolerance platform, which could lead to enhanced therapeutic outcomes for patients. Furthermore, the upcoming initial results for Descartes-08 in systemic lupus erythematosus (SLE) suggest promising advancements, especially in a landscape set by prior Auto-CAR-T therapies.

Bears say

Cartesian Therapeutics Inc is currently facing challenges that warrant a negative outlook, primarily due to a downward adjustment in projected financial targets, which may indicate concerns about the company’s growth trajectory and overall market confidence. Additionally, the repeated mention of lowering the target suggests potential underlying issues affecting revenue expectations and operational performance. These factors combined could contribute to increasing skepticism among investors regarding the company's ability to effectively leverage its ImmTOR immune tolerance platform and mRNA technology in a competitive biopharmaceutical landscape.

RNAC has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Strong Buy based on their latest research and market trends.

According to 4 analysts, RNAC has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.